Due to decades of overuse of Anti-Biotics, a new threat has emerged – Nightmare Bacteria. These Drug-resistant organisms called carbapenem-resistant Enterobacteriaceae, or CRE, were not only spreading rapidly through U.S. hospitals, they are becoming more resistant to “last-resort” antibiotics. “CRE are nightmare bacteria,” said CDC Director Dr. Tom Frieden.

How Nightmarish?

According to data from the CDC, 1 in 2 patients who contract a bloodstream CRE infection will die. But its not the most scariest thing about this organism.

The most unusual thing about this bacteria is that it has the ability to transfer its antibiotic resistance to other bacteria. It means that this bacteria can make the other common bacteria resistant to antibiotics and then all the treatment methods will be gone.

How it Works?

Once this bacteria enters the blood stream, it makes you sick. The use of antibiotics kills all other bacteria but this one remains and grow stronger. Then it transfer its antibiotic resistance to remaining bacteria which make them virtually resistant to any type of medical treatment.

The miracle age of antibiotics could be coming to an end

“The world is entering a post-antibiotic era. Doctors tell me there are patients for whom we have no therapy. The bacteria are growing stronger, and the drug pipeline is drying up,” says award-winning journalist David E. Hoffman, who investigates the crisis for FRONTLINE.

There is nothing to be jump off from your chairs. All bacteria can become resistant to antibiotic with moderate use of it in laboratories. Now due to the overdose of antibiotic since last decade our bodies are acting as laboratories to make them stronger. The only concern is Governments and other concerned agencies are not taking serious steps to handle this. Where are the new antibiotics? The answer is antibiotics are used for very limited timespan.

Dr. John Rex, V.P. Clinical Research for AstraZeneca, explains:

“It can easily cost up to a billion dollars to bring a new drug to the market, and the initial reaction to it is, that’s great; let’s not use it. Let’s use it as little as possible. “

So companies don’t want to spend billions to invent new drugs with negligible returns.